AMERICAN HEART JOURNAL[ta] - Search Results

Year	Number of Results
1945	24
1946	135
1947	144
1948	176
1949	148
1950	188
1951	161
1952	189
1953	169
1954	181
1955	176
1956	168
1957	207
1958	181
1959	192
1960	205
1961	194
1962	206
1963	226
1964	263
1965	241
1966	258
1967	247
1968	232
1969	265
1970	258
1971	279
1972	285
1973	253
1974	302
1975	282
1976	291
1977	297
1978	308
1979	309
1980	339
1981	379
1982	456
1983	481
1984	561
1985	541
1986	505
1987	549
1988	567
1989	508
1990	554
1991	667
1992	629
1993	625
1994	493
1995	441
1996	463
1997	279
1998	371
1999	515
2000	380
2001	353
2002	345
2003	406
2004	410
2005	434
2006	506
2007	459
2008	440
2009	344
2010	360
2011	326
2012	321
2013	372
2014	320
2015	357
2016	335
2017	317
2018	306
2019	271
2020	312
2021	275
2022	143

1

A current review of COVID-19 for the cardiovascular specialist.

Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. Lang JP, et al. Am Heart J. 2020 Aug;226:29-44. doi: 10.1016/j.ahj.2020.04.025. Epub 2020 May 3. Am Heart J. 2020. PMID: 32497913 Free PMC article. Review.

2

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.

Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Sarraju A, et al. Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22. Am Heart J. 2021. PMID: 33358942 Clinical Trial.

3

Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.

Cox ZL, Collins SP, Aaron M, Hernandez GA, Iii ATM, Davidson BT, Fowler M, Lindsell CJ, Jr FEH, Jenkins CA, Kampe C, Miller KF, Stubblefield WB, Lindenfeld J. Cox ZL, et al. Am Heart J. 2021 Feb;232:116-124. doi: 10.1016/j.ahj.2020.10.071. Epub 2020 Nov 2. Am Heart J. 2021. PMID: 33144086

4

Diagnosis, prevention, and management of delirium in the intensive cardiac care unit.

Cortés-Beringola A, Vicent L, Martín-Asenjo R, Puerto E, Domínguez-Pérez L, Maruri R, Moreno G, Vidán MT, Fernando Arribas, Bueno H. Cortés-Beringola A, et al. Am Heart J. 2021 Feb;232:164-176. doi: 10.1016/j.ahj.2020.11.011. Epub 2020 Nov 28. Am Heart J. 2021. PMID: 33253676 Review.

5

Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol.

Chow CK, Atkins ER, Billot L, Chalmers J, Hillis GS, Hay P, Neal B, Nelson M, Patel A, Reid CM, Schlaich M, Usherwood T, Webster R, Rodgers A. Chow CK, et al. Am Heart J. 2021 Jan;231:56-67. doi: 10.1016/j.ahj.2020.09.017. Epub 2020 Oct 2. Am Heart J. 2021. PMID: 33017580 Free PMC article. Clinical Trial.

6

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.

Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Capell WH, et al. Am Heart J. 2021 May;235:12-23. doi: 10.1016/j.ahj.2021.02.001. Epub 2021 Feb 9. Am Heart J. 2021. PMID: 33577800 Free PMC article. Clinical Trial.

7

Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.

Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Ramacciotti E, Damini LP, Bronhara B, Cavalcanti AB, Rosa RG, Azevedo LCP, Veiga VC, Machado FR, Ritt LE, Martins PA, Alexander JH, Avezum A, Berwanger O; Coalition COVID-19 Brazil IV Investigators. Lopes RD, et al. Am Heart J. 2021 Aug;238:1-11. doi: 10.1016/j.ahj.2021.04.005. Epub 2021 Apr 20. Am Heart J. 2021. PMID: 33891907 Free PMC article. Clinical Trial.

8

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.

Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM. Ryan DH, et al. Am Heart J. 2020 Nov;229:61-69. doi: 10.1016/j.ahj.2020.07.008. Epub 2020 Jul 17. Am Heart J. 2020. PMID: 32916609 Free article.

9

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.

Ramacciotti E, Agati LB, Calderaro D, Volpiani GG, de Oliveira CCC, Aguiar VCR, Rodrigues E, Sobreira ML, Joviliano EE, Dusilek C, Itinose K, Dedivitis RA, Cortina AS, Sanches SMV, de Moraes NF, Tierno PFGMM, de Oliveira ALML, Tachibana A, Chate RC, Santos MVB, Cavalcante BBM, Moreira RCR, Chiann C, Tafur A, Spyropoulos AC, Lopes RD. Ramacciotti E, et al. Am Heart J. 2021 Dec;242:115-122. doi: 10.1016/j.ahj.2021.08.016. Epub 2021 Sep 1. Am Heart J. 2021. PMID: 34480880 Free PMC article. Clinical Trial.

10

Modifiable lifestyle factors and heart failure: A Mendelian randomization study.

van Oort S, Beulens JWJ, van Ballegooijen AJ, Handoko ML, Larsson SC. van Oort S, et al. Am Heart J. 2020 Sep;227:64-73. doi: 10.1016/j.ahj.2020.06.007. Epub 2020 Jun 15. Am Heart J. 2020. PMID: 32682105 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results